SELB

Selecta Biosciences, Inc. (SELB) | Rumor.io

Selecta Biosciences

SELB

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SELB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Nov 13

Selecta Biosciences, Inc. ($SELB) has announced a merger with Cartesian Therapeutics, creating a fully integrated company pioneering RNA cell therapy for autoimmune disease.
The combined company will have a cash balance of over $110M and a pipeline that includes a BCMA-targeting, mRNA-based CAR-T therapy for autoimmune disease.
The merger will require a stock split, and the company's thesis has changed, requiring a different investment approach, with trading halted and resuming shortly after the announcement.

Generated by AI

Sentiment

Of the messages about SELB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +4.17
Bearish	0%	0%	0%	0% -4.17

Feb 4

Selecta Biosciences' ImmTOR technology has the potential to drive growth and make the company a strong long-term hold.
The company's stock price has the potential to increase to $15 or more in the long term, making it a worthwhile investment.
Selecta Biosciences' charts suggest a possible 2-3 day rally, making it a good time to buy and load up on shares.

Generated by AI

Topics

Of the messages about SELB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 7

Selecta Biosciences, Inc. ($SELB) hosts Q3 earnings call today at 8:30 AM Eastern.
Q3 2017 earnings call will be live-streamed and available for replay.
Q3 2017 earnings call will be available on-demand after the live broadcast.

Announcements· Mar 21

Selecta Biosciences' gout drug development and commercialization rights were licensed to Sobi in 2020 for $75M upfront, plus a $25M equity investment, with potential milestone payments of $630M.
Selecta Biosciences filed an 8-K form with the SEC on March 21, disclosing Regulation FD information and other events.
The 8-K filing relates to Selecta Biosciences' SEC filing, providing details on the company's announcements and events.

Technical Analysis· Feb 3

SELB is gapping up without a known catalyst, showing good price action on okay volume in premarket.
The stock is currently showing weakness after failing to overcome premarket resistance at 5.74.
If SELB can get back up and cross the resistance at 5.74, it may be worth keeping an eye on.

Generated by AI

Community

Of the messages about SELB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· Mar 21

Selecta Biosciences' stock surged ~20% as its gout drug SEL-212 met the main goal in 2 phase 3 trials, according to recent data.
The company had to pivot and enroll patients in the US due to the pandemic and war in Ukraine, which interrupted phase 2 and 3 studies, respectively.
The gout drug SEL-212 has shown promise, meeting the main goal in 2 trials, but the stock's price action is unclear, with some analysts questioning the data and others seeing a positive trend.

Newcomers· Aug 5

$SELB shares gained 31% today, with the post asking what's behind the sudden increase.
The post mentions $SELB in a list of symbols, noting that DCPH shares are trading 25% higher, but doesn't provide specific information on SELB.
The post is ambiguous, stating that SELB should be fun and keeping the mind sharp, but doesn't offer any market-related insights or analysis.

Generated by AI

Also Discussed

Investors talking about SELB also mention

#	Name	Attention
1	Cartesian Therapeutics, Inc.RNAC	0%0
2	JNCE - Jounce Therapeutics, Inc.	——
3	ORTX - Orchard Therapeutics plc	——
4	NLTX - Neoleukin Therapeutics, Inc.	——
5	PRTK - Paratek Pharmaceuticals, Inc.	——
6	Palvella Therapeutics IncPIRS	0%0
7	KMPH - KemPharm, Inc.	——
8	Addex Therapeutics LtdADXN	0%0
9	REPH - Recro Pharma, Inc.	——
10	Crescent Biopharma Inc.CBIO	0%new